Actively Recruiting
Autologous CAR-T Cells Targeting B7-H3 in PDAC
Led by UNC Lineberger Comprehensive Cancer Center · Updated on 2026-03-19
27
Participants Needed
1
Research Sites
297 weeks
Total Duration
On this page
Sponsors
U
UNC Lineberger Comprehensive Cancer Center
Lead Sponsor
M
M.D. Anderson Cancer Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this gene therapy research study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9.CAR.B7-H3 T cells) in patients with pancreatic ductal adenocarcinoma that came back after receiving standard therapy for this cancer. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration.
CONDITIONS
Official Title
Autologous CAR-T Cells Targeting B7-H3 in PDAC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provide written informed consent and HIPAA authorization
- Be 18 years or older at the time of consent
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Have histological or cytological confirmation of pancreatic ductal adenocarcinoma
- Female participants of childbearing potential must agree to abstain from heterosexual activity or use two effective contraception methods from consent until 6 months after treatment ends
- Male participants with female partners must have had a prior vasectomy or agree to use adequate contraception from first dose through 3 months after cell infusion therapy
You will not qualify if you...
- Have a prior or current malignancy that could interfere with safety or efficacy assessments
- Be unwilling or unable to comply with study procedures based on investigator judgment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States, 27599
Actively Recruiting
Research Team
C
Catherine Cheng
CONTACT
C
Caroline Babinec
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here